Bruker Corporation (BRKR)

Bruker Corp.'s stock price has declined approximately 37.8% between October 2024 and October 2025 due to a challenging macro environment and margin pressure. A $600 million mandatory convertible preferred stock sale in September 2025 led to a nearly 10% drop in shares. Weak 2025 results and a cautious 2026 outlook have contributed to a 40% decline in shares since January 2026.

The global scientific instruments industry experiences steady demand, with an average annual growth rate of about 5%. Bruker observed weaker demand for academic and research instruments in the first half of 2025, but the third quarter of 2025 showed strength in bookings within the academic/government market segment. Spatial biology orders demonstrated double-digit percentage organic growth in the fourth quarter of 2025. Bruker's BEST division received a substantial combined order value of $500 million for next-generation MRI magnets at the beginning of 2026.

Bruker Corp. is an American manufacturer of high-performance scientific instruments and analytical and diagnostic solutions, operating primarily in the Healthcare sector. The company is divided into four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST). Major products include mass spectrometers, X-ray diffractometers, NMR spectroscopy devices, and various diagnostic kits. Bruker has expanded its portfolio through acquisitions, including NanoString Technologies and ELITechGroup.

Bruker Corporation is headquartered in Billerica, Massachusetts, U.S., with a significant global presence of over 11,000 employees across more than 90 locations. International sales constituted 74% of its revenue in 2025. Manufacturing facilities are located in Karlsruhe, Germany, and Madison, Wisconsin.

Bruker has a strong reputation for innovation and high-performance scientific instruments. The company sponsors the Fritz Feigl Prize and the Günther Laukien Prize. Recent advancements in spatial biology, proteomics, and multiomics solutions have been well-received. There is no specific information indicating events that have negatively impacted Bruker's brand reputation in the past year.

Ownership of Bruker Corporation is predominantly held by institutional investors, accounting for approximately 81.91% of shares as of August 2025. Key institutional shareholders include T. Rowe Price Investment Management, Inc., Vanguard Fiduciary Trust Co., and BlackRock, Inc. Individual ownership is concentrated within the Laukien family, with Frank H. Laukien being the largest individual stockholder, holding approximately 25.62% of shares as of August 2025. Collective insider ownership is approximately 65.53% as of August 2025.